Trastuzumab cardiotoxicity moa. Apr 25, 2023 · This review explores the mechanisms of trastuzumab-mediated cardiotoxicity, as well as the physiological effects of exercise on the heart, in order to assess the suitability of exercise intervention for breast cancer patients on trastuzumab antibody-therapy. Trastuzumab has been implicated in causing instances of transient serum enzyme elevations, but has only rarely been linked to instances of clinically apparent liver injury with jaundice Feb 19, 2014 · ABSTRACT: Great advances have been made in the arena of cancer drug therapy. Dec 17, 2024 · The cardiotoxicity of other antineoplastic drugs, including anthracyclines and taxanes, management of heart failure, and clinical use of trastuzumab and other HER2-targeted therapies are discussed separately. This review summarizes the risk factors, imaging, and prevention of cardiotoxicity associated with trastuzumab and other HER2-targeted therapies. Feb 25, 2025 · After the initial RCT in patients with metastatic breast cancer demonstrated a high rate of cardiac toxicity with concurrent administration of anthracyclines and trastuzumab, 3 subsequent clinical trials using these therapies sequentially have documented a lower prevalence of CTRCD, ranging from 4% to 14%, and of symptomatic HF, ranging from 0. 2,11 Cardiac dysfunction from trastuzumab is not dose-related and is reported to be highly reversible so patients have relatively good prognosis The key findings related to trastuzumab history are summarized in Figure 1. Purpose: Despite great success as a targeted breast cancer therapy, trastuzumab use may be complicated by heart failure and loss of left ventricular contractile function. Apr 25, 2024 · Our review reevaluates trastuzumab-induced cardiotoxicity, advocating for tailored cardiac surveillance on the basis of anthracycline exposure and risk factors. The advent of these various targeted therapies, however, has increased the incidence of cardiotoxicity-related events in cancer patients. 63–65 Some studies Cardiotoxicity has been reported with trastuzumab. Understanding risk factors for trastuzumab-induced cardiotoxicity and appropriate patient monitoring during trastuzumab treatment allows for safe and effective use of this important adjuvant therapy. In this review, we discuss different mechanisms of action proposed for trastuzumab. Aug 10, 2018 · This review highlights novel discovery of DNA Topoisomerase II as a shared target for anthracycline and trastuzumab-induced cardiotoxicity and speculates on cardiac risks associated with trastuzumab and immune checkpoint-based therapies. Feb 1, 2016 · Trastuzumab-associated cardiotoxicity was first recognized as an unanticipated adverse effect in the late 1990s during the early trials in metastatic human epidermal growth factor receptor 2 (HER2)–positive breast cancer, as reported by the independent Cardiac Review and Evaluation Committee. After demonstrating the clinical benefits of trastuzumab, many studies were carried out in an attempt to unravel the mechanisms of action of trastuzumab. Jun 22, 2024 · Trastuzumab is an FDA-approved antineoplastic biologic that targets HER2-positive breast and gastric cancer. This activity outlines trastuzumab's various indications and off-label uses, including its combination with anthracycline or taxane-based chemotherapy for breast cancer, as monotherapy or in combination with paclitaxel for metastatic breast cancer, and in combination with cisplatin Jul 5, 2007 · The absence of a relevant animal model and the paucity of cardiac-biopsy specimens from affected patients has limited our understanding of the cardiotoxicity of trastuzumab. 10 In seven studies, the Cardiac Review and Trastuzumab is a humanized monoclonal antibody to the human epidermal growth factor receptor 2 (HER2) which is used in combination with other antineoplastic agents in the therapy of breast and gastric cancer. It is crucial that . Signs and symptoms include: dyspnea, increased cough, paroxysmal nocturnal dyspnea, peripheral edema, S3 gallop, congestive heart failure (CHF), or a reduced ejection fraction of 10% or greater. A number of modalities, such as targeted therapies, have emerged that have drastically changed the clinical landscape of cancer-related drug therapy. xmwmj jtjfawq oztvw ree ugvlkxip btkl azfuvk qzxh uzcvl dfwhq